Carsten Jessen

Title: Carsten Jessen: Innovator in Selective PYY Compounds

Introduction

Carsten Jessen is a notable inventor based in Birkeroed, Denmark. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of selective PYY compounds. With a total of 3 patents to his name, Jessen's work has the potential to impact medical treatments significantly.

Latest Patents

Jessen's latest patents focus on innovative PYY compounds. The first patent describes PYY compounds that have the amino acid in the position corresponding to position 30 of hPYY(1-36) substituted with tryptophan and derivatives thereof. These compounds act as selective Y2 receptor agonists and are accompanied by pharmaceutical compositions that include these PYY compounds and pharmaceutically acceptable excipients. The second patent also relates to PYY compounds with specific amino acid modifications, including 7Lys, 30Trp, and 31Leu, along with additional modifications. Similar to the first, these compounds serve as selective Y2 receptor agonists and are intended for medical use.

Career Highlights

Carsten Jessen is currently associated with Novo Nordisk A/S, a leading global healthcare company. His work at Novo Nordisk has allowed him to focus on innovative research and development in the pharmaceutical sector. Jessen's expertise in selective PYY compounds showcases his commitment to advancing medical science.

Collaborations

Jessen collaborates with esteemed colleagues, including Soeren Oestergaard and Birgitte Schjellerup Wulff. Their combined efforts contribute to the innovative research environment at Novo Nordisk.

Conclusion

Carsten Jessen's contributions to the field of selective PYY compounds highlight his role as a significant inventor in pharmaceutical sciences. His patents and ongoing research have the potential to lead to advancements in medical treatments.